search
Back to results

A Safety and PK Study of IV Eravacycline

Primary Purpose

Bacterial Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Eravacycline (TP-434)
Sponsored by
Tetraphase Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bacterial Infections

Eligibility Criteria

8 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female from 8 to <18 years of age on the day informed consent (and assent, if applicable) is obtained
  2. Written informed consent from parent(s) or other legally authorized representative(s) and informed assent from subject (if age appropriate according to local requirements)
  3. Hospitalized, in stable condition, and receiving or plan to receive within 24 hours systemic antibiotic therapy, other than eravacycline, for a suspected or confirmed bacterial infection
  4. Likely to survive the current illness
  5. In the Investigator's opinion, the subject will require hospitalization for at least 24 hours following administration of the study drug
  6. The subject appears to have sufficient intravascular access (peripheral or central) to receive study drug

Exclusion Criteria:

  1. Evidence or history of a clinically significant medical condition that may, in the assessment of the Investigator, impair study participation or pose a significant safety risk or diminish the subject's ability to undergo all study procedures and assessments
  2. Received an investigational product and/or device within 30 days prior to study drug administration or is currently enrolled in any other clinical study involving an investigational product or any other type of medical treatment judged by the Investigator, in consultation with the Medical Monitor, not to be scientifically or medically compatible with this study
  3. History of hypersensitivity to tetracycline antibiotics
  4. Prior dosing in this protocol
  5. Unlikely to survive at least 48 hours following administration of study drug
  6. Unable or unwilling, in the judgment of the Investigator, to comply with the protocol
  7. Subject is a child of an employee of the Investigator or study center who has direct involvement in the proposed study or other studies under the direction of the same Investigator or study center, or an immediate family member of the employee or the Investigator, defined as a spouse, parent, child, or sibling, whether biological or legally adopted
  8. Breastfeeding females
  9. Females of childbearing potential [those with menarche and/or thelarche (beginning of breast development)] and sexually active males who are unwilling or unable to use an acceptable method of contraception
  10. Positive pregnancy test in females of childbearing potential
  11. Any other circumstance that, in the opinion of the Investigator, would preclude subject participation in the study

Sites / Locations

  • Ronald Reagan University of California Los Angeles Medical Center
  • Lurie Children's Hospital
  • Louisiana State University Health Sciences Center
  • Tufts Medical Center
  • Duke University Medical Center
  • University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital
  • West Virginia University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1

Cohort 2

Arm Description

Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age. Age group (years) Dose (mg/kg) 12 to <18 (Cohort 1) 1.50

Eravacycline will be administered as a single 60 minute IV infusion according to age. Age group (years) Dose (mg/kg) 8 to <12 (Cohort 2) 1.75

Outcomes

Primary Outcome Measures

Assess the Pharmacokinetics (PK) parameters for Cmax, maximum observed plasma concentration
Cmax, maximum observed plasma concentration
Assess the Pharmacokinetics (PK) parameters for AUC0-t, area under the plasma concentration-time curve
AUC0-t, area under the plasma concentration
Assess the Pharmacokinetics (PK) parameters for AUC0-inf, area under the plasma concentration-time curve extrapolated to infinite time
AUC0-inf, area under the plasma concentration-time curve extrapolated to infinite time
Assess the Pharmacokinetics (PK) parameters for AUC0-24, area under the plasma concentration-time curve from time 0 to 24 hours after dose
AUC0-24, area under the plasma concentration-time curve from time 0 to 24 hours after dose
Assess the Pharmacokinetics (PK) parameters for t1/2, elimination half-life
t1/2, elimination half-life
Assess the Pharmacokinetics (PK) parameters for Clast,, last observed plasma concentration
Clast, last observed plasma concentration
Assess the Pharmacokinetics (PK) parameters for CL, systemic clearance
CL, systemic clearance
Assess the Pharmacokinetics (PK) parameters for Vd, volume of distribution
Vd, volume of distribution

Secondary Outcome Measures

Adverse Events
Assess Adverse Events to assess safety and tolerability
A Directed Physical examination including chest/respiratory
Changes in Physical examination findings including chest/respiratory
A Directed Physical examination including heart/cardiovascular
Changes in Physical examination findings including heart/cardiovascular
Vital Signs including blood pressure
Changes in blood pressure
Vital Signs including heart rate
Changes in heart rate
Vital Signs including respiratory rate
Changes in respiratory rate
Vital Signs including body temperature
Changes in body temperature
Safety laboratory results including clinical chemistry
Changes in Clinical laboratory tests including clinical chemistry
Safety laboratory tests including hematology
Changes in Clinical laboratory tests including hematology

Full Information

First Posted
September 26, 2018
Last Updated
December 1, 2021
Sponsor
Tetraphase Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03696550
Brief Title
A Safety and PK Study of IV Eravacycline
Official Title
A Phase 1, Open-label, Multicenter Study to Determine the Pharmacokinetics and Safety of Intravenous Eravacycline in Children With Suspected or Confirmed Bacterial Infection
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
December 20, 2018 (Actual)
Primary Completion Date
March 14, 2021 (Actual)
Study Completion Date
March 19, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tetraphase Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 1, open-label, multi-center study to determine the pharmacokinetics and safety of intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection. Male and Female subjects from 8 to <18 years of age who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Detailed Description
This is a Phase 1, open-label, single dose study to evaluate PK, safety, and tolerability of IV eravacycline in children with suspected or confirmed bacterial infection who are receiving systemic antibiotic therapy, other than eravacycline. The study design will allow for evaluation of PK and safety of IV eravacycline in a pediatric population at exposures predicted to be comparable to those already studied in adults. The study design is depicted in Figure 1. Two cohorts defined by age group will be enrolled simultaneously: Cohort 1: 12 to <18 years of age (adolescents) Cohort 2: 8 to <12 years of age (younger children) Eravacycline will be administered as a single IV dose using the optimum dosage determined from PK-PD modeling and model-based simulations of phase 1, 2, and 3 adult data. Blood samples will be collected for PK analysis at predetermined timepoints.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age. Age group (years) Dose (mg/kg) 12 to <18 (Cohort 1) 1.50
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
Eravacycline will be administered as a single 60 minute IV infusion according to age. Age group (years) Dose (mg/kg) 8 to <12 (Cohort 2) 1.75
Intervention Type
Drug
Intervention Name(s)
Eravacycline (TP-434)
Other Intervention Name(s)
Trade name: Xerava™
Intervention Description
Subjects will be stratified by age into 2 cohorts, as follows: Cohort 1: from 12 to <18 years of age (N=8) Cohort 2: from 8 to <12 years of age (N=12 or at least 60% of subjects)
Primary Outcome Measure Information:
Title
Assess the Pharmacokinetics (PK) parameters for Cmax, maximum observed plasma concentration
Description
Cmax, maximum observed plasma concentration
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for AUC0-t, area under the plasma concentration-time curve
Description
AUC0-t, area under the plasma concentration
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for AUC0-inf, area under the plasma concentration-time curve extrapolated to infinite time
Description
AUC0-inf, area under the plasma concentration-time curve extrapolated to infinite time
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for AUC0-24, area under the plasma concentration-time curve from time 0 to 24 hours after dose
Description
AUC0-24, area under the plasma concentration-time curve from time 0 to 24 hours after dose
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for t1/2, elimination half-life
Description
t1/2, elimination half-life
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for Clast,, last observed plasma concentration
Description
Clast, last observed plasma concentration
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for CL, systemic clearance
Description
CL, systemic clearance
Time Frame
Screening (-2 to 1) to Day 7
Title
Assess the Pharmacokinetics (PK) parameters for Vd, volume of distribution
Description
Vd, volume of distribution
Time Frame
Screening (-2 to 1) to Day 7
Secondary Outcome Measure Information:
Title
Adverse Events
Description
Assess Adverse Events to assess safety and tolerability
Time Frame
From the time of signing the informed consent form to Day 7
Title
A Directed Physical examination including chest/respiratory
Description
Changes in Physical examination findings including chest/respiratory
Time Frame
Screening (-2 to 1) to Day 7.
Title
A Directed Physical examination including heart/cardiovascular
Description
Changes in Physical examination findings including heart/cardiovascular
Time Frame
Screening (-2 to 1) to Day 7.
Title
Vital Signs including blood pressure
Description
Changes in blood pressure
Time Frame
Screening (-2 to 1) to Day 7
Title
Vital Signs including heart rate
Description
Changes in heart rate
Time Frame
Screening (-2 to 1) to Day 7
Title
Vital Signs including respiratory rate
Description
Changes in respiratory rate
Time Frame
Screening (-2 to 1) to Day 7
Title
Vital Signs including body temperature
Description
Changes in body temperature
Time Frame
Screening (-2 to 1) to Day 7
Title
Safety laboratory results including clinical chemistry
Description
Changes in Clinical laboratory tests including clinical chemistry
Time Frame
Screening (-2 to 1) to Day 7
Title
Safety laboratory tests including hematology
Description
Changes in Clinical laboratory tests including hematology
Time Frame
Screening (-2 to 1) to Day 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female from 8 to <18 years of age on the day informed consent (and assent, if applicable) is obtained Written informed consent from parent(s) or other legally authorized representative(s) and informed assent from subject (if age appropriate according to local requirements) Hospitalized, in stable condition, and receiving or plan to receive within 24 hours systemic antibiotic therapy, other than eravacycline, for a suspected or confirmed bacterial infection Likely to survive the current illness In the Investigator's opinion, the subject will require hospitalization for at least 24 hours following administration of the study drug The subject appears to have sufficient intravascular access (peripheral or central) to receive study drug Exclusion Criteria: Evidence or history of a clinically significant medical condition that may, in the assessment of the Investigator, impair study participation or pose a significant safety risk or diminish the subject's ability to undergo all study procedures and assessments Received an investigational product and/or device within 30 days prior to study drug administration or is currently enrolled in any other clinical study involving an investigational product or any other type of medical treatment judged by the Investigator, in consultation with the Medical Monitor, not to be scientifically or medically compatible with this study History of hypersensitivity to tetracycline antibiotics Prior dosing in this protocol Unlikely to survive at least 48 hours following administration of study drug Unable or unwilling, in the judgment of the Investigator, to comply with the protocol Subject is a child of an employee of the Investigator or study center who has direct involvement in the proposed study or other studies under the direction of the same Investigator or study center, or an immediate family member of the employee or the Investigator, defined as a spouse, parent, child, or sibling, whether biological or legally adopted Breastfeeding females Females of childbearing potential [those with menarche and/or thelarche (beginning of breast development)] and sexually active males who are unwilling or unable to use an acceptable method of contraception Positive pregnancy test in females of childbearing potential Any other circumstance that, in the opinion of the Investigator, would preclude subject participation in the study
Facility Information:
Facility Name
Ronald Reagan University of California Los Angeles Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Lurie Children's Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Louisiana State University Health Sciences Center
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Facility Name
Tufts Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
West Virginia University Hospital
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Safety and PK Study of IV Eravacycline

We'll reach out to this number within 24 hrs